Administration of norUDCA (3), ASBT inhibitors (37, 38), or a bile acid sequestrant (39) have shown benefit in the Abcb4–/– mouse model of cholestasis and appear to involve overlapping and complementary therapeutic mechanisms of action. Here, SLC10A2 is linked to cholestasis.